Antitrust Antitrust

Teva faces EU dominance probe over multiple sclerosis treatment

By Lewis Crofts
  • 06 Nov 2020 10:20
  • 06 Nov 2020 10:20
Teva was visited by EU antitrust officials in October 2019 as part of a probe into whether it had abused its market clout related to a treatment for multiple sclerosis, the pharmaceutical company has said.

In a filing to investors, Teva said it had also received follow-up questions from the European Commission and

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News